Genomic Reassurance and Diagnostic Closure in Precision Oncology: A Preventable Hazard
Clinical Pharmacology & Therapeutics · 08.11.2026
DOI: 10.1002/cpt.70557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.11.2026. Verfasst von John D Schuetz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Genomic findings can sharpen therapeutic decisions, but they can also provide false reassurance. In precision oncology, labels such as benign, nonactionable, or explanatory may be mistaken for evidence that symptoms or abnormal findings require no further evaluation. This Perspective argues that genotype–phenotype discordance should be treated as a safety signal. Simple report language, tumor‐board checks, and artificial intelligence guardrails can preserve the value of genomics without allowing a molecular explanation to become diagnostic closure.
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
- Division of Clinical Pharmacology, Western University, London, ON, Canada.
ORCID-Profile: John D Schuetz, Richard B Kim
Zitieren
APA
Schuetz, J. D., & Kim, R. B. (2026). Genomic Reassurance and Diagnostic Closure in Precision Oncology: A Preventable Hazard. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70557
Vancouver
Schuetz JD, Kim RB. Genomic Reassurance and Diagnostic Closure in Precision Oncology: A Preventable Hazard. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70557
BibTeX
@article{Schuetz2026,
author = {Schuetz, John D and Kim, Richard B},
title = {Genomic Reassurance and Diagnostic Closure in Precision Oncology: A Preventable Hazard},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70557}
}
EUVIMED